Janux Therapeutics, Inc. (NASDAQ:JANX) Receives $79.17 Average PT from Analysts

Shares of Janux Therapeutics, Inc. (NASDAQ:JANX) have been assigned a consensus rating of “Moderate Buy” from the sixteen brokerages that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation, twelve have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $79.1667.

A number of equities analysts have commented on the company. Truist Financial started coverage on Janux Therapeutics in a research note on Wednesday, September 10th. They set a “buy” rating and a $100.00 price objective on the stock. HC Wainwright restated a “buy” rating and issued a $70.00 price target on shares of Janux Therapeutics in a research report on Tuesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Janux Therapeutics in a research report on Wednesday, October 8th. Barclays increased their price objective on shares of Janux Therapeutics from $47.00 to $48.00 and gave the stock an “overweight” rating in a research note on Friday, November 7th. Finally, Wedbush restated an “outperform” rating and issued a $76.00 target price on shares of Janux Therapeutics in a research report on Friday, November 7th.

Janux Therapeutics Stock Performance

NASDAQ:JANX opened at $31.53 on Tuesday. Janux Therapeutics has a 52 week low of $21.73 and a 52 week high of $71.71. The firm’s 50-day simple moving average is $26.21 and its 200 day simple moving average is $25.08. The firm has a market cap of $1.90 billion, a price-to-earnings ratio of -18.77 and a beta of 2.83.

Janux Therapeutics (NASDAQ:JANX) last announced its earnings results on Thursday, November 6th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.21. The business had revenue of $10.00 million for the quarter, compared to analyst estimates of $3.07 million. Sell-side analysts anticipate that Janux Therapeutics will post -1.38 EPS for the current year.

Insider Buying and Selling

In other Janux Therapeutics news, insider Andrew Hollman Meyer sold 16,665 shares of the company’s stock in a transaction on Tuesday, October 28th. The stock was sold at an average price of $30.06, for a total transaction of $500,949.90. Following the completion of the sale, the insider directly owned 82,139 shares in the company, valued at $2,469,098.34. This represents a 16.87% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 29.40% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. US Bancorp DE lifted its holdings in shares of Janux Therapeutics by 2,402.9% in the first quarter. US Bancorp DE now owns 1,727 shares of the company’s stock worth $47,000 after acquiring an additional 1,658 shares during the last quarter. Osaic Holdings Inc. boosted its position in Janux Therapeutics by 704.6% in the second quarter. Osaic Holdings Inc. now owns 3,468 shares of the company’s stock valued at $80,000 after buying an additional 3,037 shares in the last quarter. Virtus Investment Advisers LLC increased its holdings in shares of Janux Therapeutics by 37.9% during the second quarter. Virtus Investment Advisers LLC now owns 3,679 shares of the company’s stock worth $85,000 after buying an additional 1,011 shares in the last quarter. Tower Research Capital LLC TRC boosted its holdings in shares of Janux Therapeutics by 175.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 3,928 shares of the company’s stock valued at $91,000 after acquiring an additional 2,502 shares in the last quarter. Finally, Ameritas Investment Partners Inc. grew its position in Janux Therapeutics by 25.6% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 4,020 shares of the company’s stock worth $93,000 after acquiring an additional 820 shares during the last quarter. Institutional investors own 75.39% of the company’s stock.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.